Last reviewed · How we verify

Placebo orodispersible tablet twice daily

Dr. Falk Pharma GmbH · Phase 3 active Small molecule

Placebo orodispersible tablet twice daily is a Small molecule drug developed by Dr. Falk Pharma GmbH. It is currently in Phase 3 development. Also known as: Placebo BID.

This drug is a placebo, meaning it has no active therapeutic effect.

At a glance

Generic namePlacebo orodispersible tablet twice daily
Also known asPlacebo BID
SponsorDr. Falk Pharma GmbH
ModalitySmall molecule
PhasePhase 3

Mechanism of action

As a placebo, it does not interact with any biological molecules or systems, and its effects are purely psychological or due to the natural course of the disease.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo orodispersible tablet twice daily

What is Placebo orodispersible tablet twice daily?

Placebo orodispersible tablet twice daily is a Small molecule drug developed by Dr. Falk Pharma GmbH.

How does Placebo orodispersible tablet twice daily work?

This drug is a placebo, meaning it has no active therapeutic effect.

Who makes Placebo orodispersible tablet twice daily?

Placebo orodispersible tablet twice daily is developed by Dr. Falk Pharma GmbH (see full Dr. Falk Pharma GmbH pipeline at /company/dr-falk-pharma-gmbh).

Is Placebo orodispersible tablet twice daily also known as anything else?

Placebo orodispersible tablet twice daily is also known as Placebo BID.

What development phase is Placebo orodispersible tablet twice daily in?

Placebo orodispersible tablet twice daily is in Phase 3.

Related